Clinical Trial Update: Fedratinib in Combination With Nivolumab [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates the combination of fedratinib and nivolumab in patients with Primary myelofibrosis or Secondary myelofibrosis and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Fedratinib (Inrebic) (fedratinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Status: COMPLETED